ANI Pharmaceuticals vs Corcept Therapeutics
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put ANI Pharmaceuticals and Corcept Therapeutics side by side, using each one’s latest annual report. Here is what stands out:
- ANI Pharmaceuticals is the larger business, with $883M of revenue in fiscal 2025 against $761M for Corcept Therapeutics.
- ANI Pharmaceuticals grew revenue faster (43.8%, against 12.8%).
- ANI Pharmaceuticals kept more of each dollar of sales as operating profit (12.6% operating margin, against 5.9%).
- ANI Pharmaceuticals turned more of its sales into free cash flow (19.4% FCF margin, against 18.6%).
Who comes out ahead
Of the 10 measures where higher (or lower) is clearly better, how many each company leads.
ANI Pharmaceuticals
ANIP
7/10
Revenue growth5-year growthOperating marginFCF marginReturn on capitalReturn on equityPiotroski F-score
Corcept Therapeutics
CORT
3/10
Net marginNet debt / EBITDAShare count change
Side by side
Best in the row
| Latest fiscal year | ANIP FY25 | CORT FY25 |
|---|---|---|
| Size | ||
| Market cap | $1.6B | $10.2B |
| Revenue | $883M | $761M |
| Free cash flow | $171M | $142M |
| Net income | $78.3M | $99.7M |
| Growth | ||
| Revenue growth | 43.8% | 12.8% |
| 5-year growth | 33.5% | 16.6% |
| Share count change | 9.9% | 5.7% |
| Profitability | ||
| Gross margin | — | 98.3% |
| Operating margin | 12.6% | 5.9% |
| Net margin | 8.9% | 13.1% |
| FCF margin | 19.4% | 18.6% |
| Return on capital | 15.9% | 15.7% |
| Return on equity | 16.6% | 15.0% |
| Balance sheet | ||
| Net debt | $23.7M | −$372M |
| Net debt / EBITDA | 0.1x | −8.1x |
| Dividends and buybacks | $13.4M | $173M |
| Valuation & quality | ||
| P/E | 15.7x | — |
| Piotroski F-score | 6 | 3 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.